Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 15/20 | 1.00 |
| ▸ | MMP3 | P08254 | 7/20 | 1.00 |
| ▸ | MMP2 | P08253 | 7/20 | 1.00 |
| ▸ | MMP9 | P14780 | 7/20 | 1.00 |
| ▸ | MMP1 | P03956 | 6/20 | 1.00 |
| ▸ | MMP7 | P09237 | 4/20 | 1.00 |
| ▸ | MMP8 | P22894 | 4/20 | 1.00 |
| ▸ | MMP13 | P45452 | 4/20 | 1.00 |
| ▸ | MMP14 | P50281 | 4/20 | 1.00 |
| ▸ | ADAM10 | O14672 | 4/20 | 1.00 |
| ▸ | ADAM33 | Q9BZ11 | 2/20 | 0.68 |
| ▸ | MMP15 | P51511 | 1/20 | 0.68 |
| ▸ | MMP16 | P51512 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29732231 | 1.00 | ADAM17 (1.00) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL6350415 | 1.00 | ADAM17 (1.00) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL6350418 | 1.00 | ADAM17 (1.00) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL6681213 | 0.93 | ADAM17 (0.86) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL6681788 | 0.91 | ADAM17 (0.84) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL6685255 | 0.91 | ADAM17 (0.84) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL4193352 | 0.90 | ADAM17 (1.00) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL8282217 | 0.90 | ADAM17 (1.00) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL8354979 | 0.90 | ADAM17 (0.82) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL4207403 | 0.90 | ADAM17 (0.82) | ADAM17MMP3MMP2MMP9MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247257-A1 | Combination | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | US | claimed |
| EP-1596847-A1 | NEW COMBINATION | AstraZeneca AB (SE) | 2005-11-23 | — | — | EP | claimed |
| WO-2004073704-A1 | NEW COMBINATION | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | WO | claimed |
| EP-3174877-B1 | INDOLIZINE DERIVATIVES WHICH ARE APPLICABLE TO NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-10676433-B2 | Indole derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2020-06-09 | — | — | US | disclosed |
| US-10323000-B2 | Indole derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2019-06-18 | — | — | US | disclosed |
| US-20190161447-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2019-05-30 | — | — | US | disclosed |
| US-9931324-B2 | Indolizine derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2018-04-03 | — | — | US | disclosed |
| US-20170079965-A1 | NOVEL INDOLIZINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| US-9546166-B2 | Indolizine derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2017-01-17 | — | — | US | disclosed |
| US-20160296509-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| EP-2243772-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2010-10-27 | — | — | EP | disclosed |
| WO-2010118921-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20090312366-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2009-12-17 | — | — | US | disclosed |
| WO-2009118175-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2009-10-01 | — | — | WO | disclosed |
| EP-2105164-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2009-09-30 | — | — | EP | disclosed |
| US-20060247257-A1 | Combination | ASTRAZENECA AB (SE) | 2006-11-02 | — | — | US | disclosed |
| EP-1596847-A1 | NEW COMBINATION | AstraZeneca AB (SE) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004073704-A1 | NEW COMBINATION | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323000-B2 | Indole derivatives and their use in neurodegenerative diseases | P2RX3, ADORA2A, P2RX7 | ADAM17 3509/4885MMP3 3319/4885MMP2 4157/4885 |
| US-20160296509-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX7, P2RX3, P2RX1 | ADAM17 3792/4885MMP3 4529/4885MMP2 4712/4885 |
| US-20190161447-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX3, P2RX7, P2RX2 | ADAM17 3322/4885MMP3 3409/4885MMP2 4288/4885 |
| US-20170079965-A1 | NOVEL INDOLIZINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX5, P2RX4, P2RX3 | ADAM17 3192/4885MMP3 3427/4885MMP2 4308/4885 |
| US-10676433-B2 | Indole derivatives and their use in neurodegenerative diseases | P2RX3, ADORA2A, P2RX7 | ADAM17 3509/4885MMP3 3319/4885MMP2 4157/4885 |
| US-20060247257-A1 | Combination | P2RX7, PCSK9, P2RX1 | ADAM17 22/4885MMP3 438/4885MMP2 384/4885 |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | P2RX3, P2RX2, P2RX1 | ADAM17 3661/4885MMP3 4048/4885MMP2 4496/4885 |
| US-20090312366-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | P2RX3, P2RX7, P2RX2 | ADAM17 3214/4885MMP3 3727/4885MMP2 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.